HomeCompareAATP vs ABBV

AATP vs ABBV: Dividend Comparison 2026

AATP yields 25.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $3.6K in total portfolio value· pulled ahead in Year 10
10 years
AATP
AATP
● Live price
25.00%
Share price
$8.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$98.8K
Annual income
$11,136.05
Full AATP calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AATP vs ABBV

📍 ABBV pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAATPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AATP + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AATP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AATP
Annual income on $10K today (after 15% tax)
$2,125.00/yr
After 10yr DRIP, annual income (after tax)
$9,465.64/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $11,590.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AATP + ABBV for your $10,000?

AATP: 50%ABBV: 50%
100% ABBV50/50100% AATP
Portfolio after 10yr
$100.5K
Annual income
$17,953.91/yr
Blended yield
17.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AATP
No analyst data
Altman Z
228.0
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AATP buys
0
ABBV buys
0
No recent congressional trades found for AATP or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAATPABBV
Forward yield25.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$98.8K$102.3K
Annual income after 10y$11,136.05$24,771.77
Total dividends collected$62.5K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AATP vs ABBV ($10,000, DRIP)

YearAATP PortfolioAATP Income/yrABBV PortfolioABBV Income/yrGap
1$13,200$2,500.00$11,550$430.00+$1.6KAATP
2$17,208$3,084.11$13,472$627.96+$3.7KAATP
3$22,170$3,757.56$15,906$926.08+$6.3KAATP
4$28,247$4,524.38$19,071$1,382.55+$9.2KAATP
5$35,611$5,387.29$23,302$2,095.81+$12.3KAATP
6$44,451$6,347.55$29,150$3,237.93+$15.3KAATP
7$54,968$7,404.96$37,536$5,121.41+$17.4KAATP
8$67,374$8,557.82$50,079$8,338.38+$17.3KAATP
9$81,893$9,803.00$69,753$14,065.80+$12.1KAATP
10← crossover$98,761$11,136.05$102,337$24,771.77$3.6KABBV

AATP vs ABBV: Complete Analysis 2026

AATPStock

Agape ATP Corporation, an investment holding company, supplies health and wellness products and health solution advisory services in Malaysia. The company offers three series of programs that consist of various services and products under the ATP Zeta Health Program, ÉNERGÉTIQUE, and BEAUNIQUE names. Its products include ATP1s Survivor Select that contains various essential nutrients required by the human body to maintain normal metabolism; ATP2 Energized Mineral Concentrate, a nutritional supplement, which supports and enhances nutritional biochemical activities; ATP3 Ionized Cal-Mag, a calcium and magnesium minerals supplement; ATP4 Omega Blend, an oil blend that provides a bio-effective balance of essential fatty acids, omega 3, and omega 6; ATP5 BetaMaxx, a natural immune enhancer; AGN-Vege Fruit Fiber, a nutrition-based formulation for intestines and stomach; AGP1 Iron to improve iron deficiency anemia; and YFA-Young Formula, an anti-aging and youthful maintenance supplement. The company also provides BEAUNIQUE Mito+, an antioxidant drink for cellular, immune, metabolic, brain, and skin health; and ORYC-Organic Youth Care Cleansing Bar, an organic cleansing soap for the skin. In addition, it offers N°1 Med-Hydration, a mask that enhances skin moisture and luminosity; N°2 Med-Whitening, a mask for boosting skin moisture level and protecting skin against UV radiation; N°3 Med-Firming, which provides protection and maintenance of the basal skin collagen production; ÉNERGÉTIQUE hyaluronic acid serum; and ÉNERGÉTIQUE mousse facial cleanser, as well as Trim+, which inhibits the activities of carbohydrates digestive enzymes that result in a reduction of the breakdown and absorption of sugars. The company was incorporated in 2016 and is based in Kuala Lumpur, Malaysia.

Full AATP Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AATP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AATP vs SCHDAATP vs JEPIAATP vs OAATP vs KOAATP vs MAINAATP vs JNJAATP vs MRKAATP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.